Concepts (267)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 34 | 2022 | 839 | 3.760 |
Why?
|
| Immunosuppressive Agents | 20 | 2020 | 514 | 3.140 |
Why?
|
| Graft Rejection | 20 | 2019 | 458 | 2.730 |
Why?
|
| Graft Survival | 22 | 2022 | 465 | 2.170 |
Why?
|
| Organ Transplantation | 6 | 2022 | 110 | 1.720 |
Why?
|
| Transplant Recipients | 7 | 2020 | 109 | 1.390 |
Why?
|
| Liver Transplantation | 7 | 2022 | 400 | 1.150 |
Why?
|
| Pharmacists | 8 | 2022 | 125 | 1.140 |
Why?
|
| Dietary Supplements | 2 | 2020 | 332 | 0.930 |
Why?
|
| Glomerular Filtration Rate | 5 | 2019 | 274 | 0.820 |
Why?
|
| Kidney Failure, Chronic | 8 | 2020 | 365 | 0.780 |
Why?
|
| Nonprescription Drugs | 1 | 2020 | 28 | 0.740 |
Why?
|
| Postoperative Complications | 7 | 2019 | 1615 | 0.730 |
Why?
|
| Induction Chemotherapy | 3 | 2017 | 39 | 0.730 |
Why?
|
| Delivery of Health Care | 3 | 2020 | 445 | 0.690 |
Why?
|
| Tacrolimus | 3 | 2019 | 127 | 0.680 |
Why?
|
| Nursing Care | 1 | 2019 | 18 | 0.680 |
Why?
|
| Abatacept | 1 | 2018 | 17 | 0.640 |
Why?
|
| Antilymphocyte Serum | 4 | 2016 | 52 | 0.640 |
Why?
|
| Certification | 1 | 2018 | 66 | 0.600 |
Why?
|
| Retrospective Studies | 29 | 2022 | 7277 | 0.580 |
Why?
|
| Pharmacy Residencies | 1 | 2016 | 18 | 0.560 |
Why?
|
| Receptors, Interleukin-2 | 2 | 2016 | 42 | 0.500 |
Why?
|
| Drug Monitoring | 4 | 2020 | 107 | 0.500 |
Why?
|
| Educational Measurement | 1 | 2016 | 254 | 0.490 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2015 | 151 | 0.470 |
Why?
|
| Humans | 54 | 2022 | 68618 | 0.450 |
Why?
|
| Middle Aged | 35 | 2020 | 21147 | 0.420 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2014 | 376 | 0.420 |
Why?
|
| Immunoglobulin G | 2 | 2015 | 481 | 0.420 |
Why?
|
| Follow-Up Studies | 13 | 2019 | 3259 | 0.390 |
Why?
|
| Clinical Competence | 1 | 2016 | 657 | 0.390 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 511 | 0.380 |
Why?
|
| Adult | 30 | 2022 | 21403 | 0.380 |
Why?
|
| Risk Factors | 16 | 2019 | 5731 | 0.380 |
Why?
|
| Tissue and Organ Procurement | 3 | 2022 | 164 | 0.350 |
Why?
|
| Critical Illness | 1 | 2011 | 191 | 0.350 |
Why?
|
| Female | 36 | 2022 | 38074 | 0.340 |
Why?
|
| Male | 35 | 2020 | 37321 | 0.330 |
Why?
|
| Incidence | 6 | 2019 | 1603 | 0.330 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2017 | 148 | 0.320 |
Why?
|
| Histocompatibility Testing | 2 | 2020 | 38 | 0.310 |
Why?
|
| Drug Therapy, Combination | 4 | 2018 | 649 | 0.300 |
Why?
|
| Pharmacy Service, Hospital | 3 | 2017 | 52 | 0.300 |
Why?
|
| Patient Selection | 3 | 2020 | 592 | 0.290 |
Why?
|
| Treatment Outcome | 15 | 2018 | 7029 | 0.290 |
Why?
|
| Drugs, Generic | 2 | 2020 | 17 | 0.290 |
Why?
|
| Aged | 16 | 2020 | 14862 | 0.290 |
Why?
|
| Prospective Studies | 9 | 2019 | 3705 | 0.290 |
Why?
|
| Pharmaceutical Services | 2 | 2020 | 47 | 0.280 |
Why?
|
| Healthcare Disparities | 3 | 2018 | 378 | 0.280 |
Why?
|
| Medication Errors | 4 | 2019 | 116 | 0.270 |
Why?
|
| Renal Insufficiency | 2 | 2020 | 121 | 0.270 |
Why?
|
| Opioid-Related Disorders | 2 | 2020 | 298 | 0.270 |
Why?
|
| Kidney Function Tests | 4 | 2019 | 114 | 0.270 |
Why?
|
| Analgesics, Opioid | 3 | 2020 | 498 | 0.260 |
Why?
|
| Models, Statistical | 2 | 2019 | 448 | 0.240 |
Why?
|
| Patient Readmission | 6 | 2016 | 267 | 0.230 |
Why?
|
| Sirolimus | 2 | 2016 | 118 | 0.230 |
Why?
|
| Young Adult | 9 | 2019 | 5717 | 0.230 |
Why?
|
| Diabetes Complications | 3 | 2014 | 249 | 0.230 |
Why?
|
| Heart Failure | 2 | 2022 | 1180 | 0.220 |
Why?
|
| Prognosis | 5 | 2019 | 2093 | 0.210 |
Why?
|
| South Carolina | 7 | 2019 | 2752 | 0.210 |
Why?
|
| Professional Role | 6 | 2020 | 80 | 0.210 |
Why?
|
| Forecasting | 2 | 2020 | 277 | 0.210 |
Why?
|
| Telemedicine | 2 | 2020 | 700 | 0.200 |
Why?
|
| Mycophenolic Acid | 3 | 2015 | 62 | 0.200 |
Why?
|
| Adolescent | 8 | 2020 | 8912 | 0.190 |
Why?
|
| Burnout, Professional | 1 | 2022 | 64 | 0.190 |
Why?
|
| Delayed Graft Function | 3 | 2022 | 39 | 0.190 |
Why?
|
| Liver Cirrhosis | 2 | 2015 | 301 | 0.190 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2022 | 117 | 0.190 |
Why?
|
| Longitudinal Studies | 7 | 2020 | 1054 | 0.190 |
Why?
|
| Therapeutic Equivalency | 1 | 2020 | 21 | 0.190 |
Why?
|
| Drug Interactions | 1 | 2020 | 289 | 0.180 |
Why?
|
| Donor Selection | 1 | 2020 | 29 | 0.170 |
Why?
|
| Heart-Assist Devices | 1 | 2022 | 221 | 0.170 |
Why?
|
| Medication Adherence | 3 | 2019 | 335 | 0.170 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2019 | 77 | 0.160 |
Why?
|
| Quality Improvement | 2 | 2013 | 413 | 0.160 |
Why?
|
| Risk Assessment | 3 | 2019 | 2007 | 0.150 |
Why?
|
| Disease Management | 1 | 2019 | 248 | 0.150 |
Why?
|
| Referral and Consultation | 2 | 2020 | 383 | 0.150 |
Why?
|
| IMP Dehydrogenase | 1 | 2007 | 2 | 0.150 |
Why?
|
| End Stage Liver Disease | 1 | 2018 | 60 | 0.140 |
Why?
|
| United States | 6 | 2020 | 7367 | 0.140 |
Why?
|
| Rabbits | 2 | 2015 | 509 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 931 | 0.140 |
Why?
|
| Histocompatibility | 1 | 2016 | 17 | 0.140 |
Why?
|
| Specialization | 1 | 2016 | 66 | 0.140 |
Why?
|
| Isoantibodies | 1 | 2016 | 35 | 0.140 |
Why?
|
| Patient Outcome Assessment | 1 | 2016 | 42 | 0.130 |
Why?
|
| Hypertension | 3 | 2014 | 1535 | 0.130 |
Why?
|
| HLA Antigens | 1 | 2016 | 82 | 0.130 |
Why?
|
| Calcineurin Inhibitors | 1 | 2016 | 24 | 0.130 |
Why?
|
| Withholding Treatment | 1 | 2016 | 35 | 0.130 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 581 | 0.130 |
Why?
|
| Epitopes | 1 | 2016 | 146 | 0.130 |
Why?
|
| Time Factors | 7 | 2019 | 4655 | 0.130 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2015 | 69 | 0.130 |
Why?
|
| Anti-Infective Agents | 2 | 2014 | 166 | 0.130 |
Why?
|
| Medical Records | 1 | 2015 | 121 | 0.130 |
Why?
|
| Obesity, Morbid | 1 | 2017 | 172 | 0.120 |
Why?
|
| Cholelithiasis | 1 | 2015 | 66 | 0.120 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 468 | 0.120 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2015 | 59 | 0.120 |
Why?
|
| Antibodies, Blocking | 1 | 2014 | 17 | 0.120 |
Why?
|
| Evidence-Based Medicine | 1 | 2017 | 438 | 0.120 |
Why?
|
| Cohort Studies | 5 | 2020 | 2358 | 0.120 |
Why?
|
| Length of Stay | 5 | 2016 | 780 | 0.120 |
Why?
|
| Thiazides | 1 | 2013 | 6 | 0.110 |
Why?
|
| Liver Failure | 1 | 2013 | 27 | 0.110 |
Why?
|
| Models, Organizational | 1 | 2014 | 97 | 0.110 |
Why?
|
| Pancreas Transplantation | 1 | 2014 | 71 | 0.110 |
Why?
|
| Coagulants | 1 | 2013 | 4 | 0.110 |
Why?
|
| Factor VIIa | 1 | 2013 | 25 | 0.110 |
Why?
|
| Hospitalization | 1 | 2019 | 978 | 0.110 |
Why?
|
| Diuretics | 1 | 2013 | 97 | 0.110 |
Why?
|
| Heparin | 1 | 2014 | 205 | 0.110 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 711 | 0.110 |
Why?
|
| Fatty Liver | 1 | 2013 | 97 | 0.110 |
Why?
|
| Hepatitis C | 1 | 2014 | 114 | 0.110 |
Why?
|
| Thrombosis | 1 | 2014 | 218 | 0.110 |
Why?
|
| Blood Loss, Surgical | 1 | 2013 | 79 | 0.100 |
Why?
|
| Algorithms | 2 | 2020 | 1196 | 0.100 |
Why?
|
| BK Virus | 1 | 2012 | 17 | 0.100 |
Why?
|
| Polyomavirus Infections | 1 | 2012 | 17 | 0.100 |
Why?
|
| Transplantation | 1 | 2012 | 23 | 0.100 |
Why?
|
| Patient Care Management | 1 | 2012 | 40 | 0.100 |
Why?
|
| Isoxazoles | 1 | 2012 | 22 | 0.100 |
Why?
|
| Biopsy | 1 | 2014 | 540 | 0.100 |
Why?
|
| Tumor Virus Infections | 1 | 2012 | 32 | 0.100 |
Why?
|
| Perioperative Care | 1 | 2013 | 100 | 0.100 |
Why?
|
| Probiotics | 1 | 2011 | 14 | 0.100 |
Why?
|
| Fish Oils | 1 | 2011 | 21 | 0.100 |
Why?
|
| Androgens | 1 | 2011 | 41 | 0.100 |
Why?
|
| Dietary Fiber | 1 | 2011 | 37 | 0.100 |
Why?
|
| Education, Continuing | 1 | 2011 | 28 | 0.100 |
Why?
|
| Glutamine | 1 | 2011 | 45 | 0.100 |
Why?
|
| Selenium | 1 | 2011 | 36 | 0.100 |
Why?
|
| Diabetic Nephropathies | 1 | 2013 | 161 | 0.100 |
Why?
|
| Zinc | 1 | 2011 | 73 | 0.100 |
Why?
|
| Arginine | 1 | 2011 | 102 | 0.090 |
Why?
|
| Blood Glucose | 1 | 2014 | 631 | 0.090 |
Why?
|
| Multivariate Analysis | 4 | 2016 | 1046 | 0.090 |
Why?
|
| Fibrinolytic Agents | 1 | 2014 | 377 | 0.090 |
Why?
|
| Continuity of Patient Care | 1 | 2012 | 170 | 0.090 |
Why?
|
| Ambulatory Care | 1 | 2013 | 340 | 0.090 |
Why?
|
| Patient Safety | 1 | 2012 | 202 | 0.090 |
Why?
|
| Antiviral Agents | 1 | 2012 | 211 | 0.090 |
Why?
|
| Child | 1 | 2020 | 6405 | 0.090 |
Why?
|
| Antihypertensive Agents | 1 | 2013 | 498 | 0.080 |
Why?
|
| Depression | 1 | 2016 | 943 | 0.080 |
Why?
|
| Chi-Square Distribution | 3 | 2016 | 546 | 0.080 |
Why?
|
| Cardiovascular Diseases | 2 | 2013 | 940 | 0.080 |
Why?
|
| Proportional Hazards Models | 3 | 2018 | 792 | 0.080 |
Why?
|
| Tissue Donors | 2 | 2022 | 195 | 0.080 |
Why?
|
| Survival Rate | 3 | 2018 | 1056 | 0.080 |
Why?
|
| Cross-Sectional Studies | 3 | 2022 | 2279 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2012 | 767 | 0.070 |
Why?
|
| Quality of Life | 3 | 2022 | 1515 | 0.070 |
Why?
|
| Age Factors | 3 | 2015 | 1864 | 0.070 |
Why?
|
| Preoperative Period | 2 | 2018 | 50 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2014 | 1085 | 0.060 |
Why?
|
| Health Care Costs | 2 | 2020 | 346 | 0.060 |
Why?
|
| Prevalence | 2 | 2022 | 1619 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2016 | 536 | 0.050 |
Why?
|
| Nitroprusside | 1 | 2022 | 42 | 0.050 |
Why?
|
| Diabetes Mellitus | 3 | 2013 | 694 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2014 | 567 | 0.050 |
Why?
|
| Policy | 1 | 2022 | 58 | 0.050 |
Why?
|
| Patient Care Team | 2 | 2015 | 311 | 0.050 |
Why?
|
| Vasodilator Agents | 1 | 2022 | 138 | 0.050 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2022 | 102 | 0.050 |
Why?
|
| Fatigue | 1 | 2022 | 132 | 0.050 |
Why?
|
| Heart Atria | 1 | 2022 | 206 | 0.050 |
Why?
|
| Biomarkers | 2 | 2016 | 1593 | 0.050 |
Why?
|
| Academic Medical Centers | 2 | 2012 | 281 | 0.050 |
Why?
|
| Waiting Lists | 1 | 2020 | 104 | 0.040 |
Why?
|
| Animals | 2 | 2015 | 20881 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2022 | 586 | 0.040 |
Why?
|
| Health Plan Implementation | 1 | 2019 | 37 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2022 | 705 | 0.040 |
Why?
|
| Echocardiography | 1 | 2022 | 515 | 0.040 |
Why?
|
| Smartphone | 1 | 2019 | 69 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2019 | 242 | 0.040 |
Why?
|
| User-Computer Interface | 1 | 2020 | 230 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2014 | 1851 | 0.040 |
Why?
|
| Pain, Postoperative | 1 | 2020 | 214 | 0.040 |
Why?
|
| Program Development | 1 | 2019 | 240 | 0.040 |
Why?
|
| Mobile Applications | 1 | 2019 | 138 | 0.040 |
Why?
|
| Kidney | 1 | 2022 | 945 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2017 | 67 | 0.040 |
Why?
|
| Societies, Pharmaceutical | 1 | 2016 | 22 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2017 | 172 | 0.030 |
Why?
|
| Internet | 1 | 2019 | 390 | 0.030 |
Why?
|
| Workflow | 1 | 2017 | 100 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2007 | 381 | 0.030 |
Why?
|
| Allografts | 1 | 2016 | 63 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2016 | 238 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2019 | 374 | 0.030 |
Why?
|
| Patient-Centered Care | 1 | 2016 | 106 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2015 | 93 | 0.030 |
Why?
|
| ROC Curve | 1 | 2016 | 392 | 0.030 |
Why?
|
| Conversion to Open Surgery | 1 | 2015 | 6 | 0.030 |
Why?
|
| Contraindications | 1 | 2015 | 52 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2018 | 326 | 0.030 |
Why?
|
| Antidepressive Agents | 1 | 2016 | 216 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2015 | 4848 | 0.030 |
Why?
|
| Health Services Research | 1 | 2015 | 209 | 0.030 |
Why?
|
| Glycemic Index | 1 | 2014 | 28 | 0.030 |
Why?
|
| Government Regulation | 1 | 2014 | 46 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 235 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 2800 | 0.030 |
Why?
|
| Superior Sagittal Sinus | 1 | 2013 | 8 | 0.030 |
Why?
|
| Everolimus | 1 | 2013 | 26 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2016 | 880 | 0.030 |
Why?
|
| Postoperative Hemorrhage | 1 | 2014 | 69 | 0.030 |
Why?
|
| Hepacivirus | 1 | 2014 | 90 | 0.030 |
Why?
|
| Hyperkalemia | 1 | 2013 | 21 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2017 | 867 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2015 | 186 | 0.030 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2014 | 155 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2014 | 202 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2014 | 163 | 0.030 |
Why?
|
| Potassium | 1 | 2013 | 168 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2007 | 848 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2015 | 384 | 0.030 |
Why?
|
| Propensity Score | 1 | 2013 | 117 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 1753 | 0.030 |
Why?
|
| Intraoperative Care | 1 | 2013 | 91 | 0.030 |
Why?
|
| Medication Reconciliation | 1 | 2012 | 18 | 0.030 |
Why?
|
| Crotonates | 1 | 2012 | 3 | 0.030 |
Why?
|
| Hydroxybutyrates | 1 | 2012 | 4 | 0.030 |
Why?
|
| Toluidines | 1 | 2012 | 5 | 0.030 |
Why?
|
| Reoperation | 1 | 2014 | 467 | 0.030 |
Why?
|
| Logistic Models | 1 | 2016 | 1420 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 212 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 1465 | 0.030 |
Why?
|
| Depressive Disorder | 1 | 2016 | 621 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2016 | 1553 | 0.030 |
Why?
|
| Risk | 1 | 2013 | 563 | 0.030 |
Why?
|
| Biotransformation | 1 | 2012 | 69 | 0.030 |
Why?
|
| Aniline Compounds | 1 | 2012 | 52 | 0.030 |
Why?
|
| Nitriles | 1 | 2012 | 68 | 0.030 |
Why?
|
| Dyslipidemias | 1 | 2012 | 98 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2016 | 1342 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2014 | 287 | 0.020 |
Why?
|
| Pharmaceutical Preparations | 1 | 2012 | 101 | 0.020 |
Why?
|
| Viral Load | 1 | 2012 | 127 | 0.020 |
Why?
|
| Recurrence | 1 | 2014 | 948 | 0.020 |
Why?
|
| Educational Status | 1 | 2012 | 273 | 0.020 |
Why?
|
| Income | 1 | 2012 | 167 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2013 | 714 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2013 | 275 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2013 | 742 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2013 | 504 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2012 | 492 | 0.020 |
Why?
|
| Interprofessional Relations | 1 | 2012 | 188 | 0.020 |
Why?
|
| Reperfusion Injury | 1 | 2013 | 320 | 0.020 |
Why?
|
| Health Surveys | 1 | 2012 | 489 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2013 | 1745 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2012 | 425 | 0.020 |
Why?
|
| Sex Factors | 1 | 2012 | 1266 | 0.020 |
Why?
|
| Comorbidity | 1 | 2012 | 1426 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2013 | 1451 | 0.020 |
Why?
|